November 30, 2023
Naveris Optimistic About HPV Liquid Biopsy Test Uptake After Medicare Coverage
This article has been updated to clarify the launch date of NavDx and Naveris’ billing policies for patients without insurance coverage.
In The News
February 25, 2022
Tumor tissue modified viral-HPV DNA test predicts HPV-driven oropharynx cancer recurrence
A blood test to detect circulating tumor DNA accurately predicted recurrence of HPV-driven oropharyngeal cancer after treatment, according to research presented at Multidisciplinary Head and Neck Cancers Symposium.
February 25, 2022
Circulating TTMV HPV Tumor DNA May Detect Recurrence of HPV-Driven Oropharyngeal Cancers
A blood test was able to accurately predict disease recurrence using circulating tumor tissue modified viral (TTMV)–human papillomavirus (HPV) DNA among patients treated for HPV-driven oropharyngeal squamous cell carcinoma, according to research presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.
February 24, 2022
Tumor tissue modified viral (TTMV)-HPV DNA biomarker test predicts recurrence of HPV-driven oropharynx cancer after treatment
A large, multi-institutional study demonstrates that a blood test to detect circulating tumor DNA can accurately predict recurrence of human papillomavirus (HPV)-driven oropharyngeal cancer following treatment.
